Paul-Ehrlich-Institut

Go to:

Information on the Use of Cookies

In order to operate and optimise our website, we would like to collect and analyse statistical information completely anonymously. Will you accept the temporary use of statistics cookies?

You can revoke your consent at any time in our privacy policy.

OK

Positions

Date Title
18.08.2023 Statement from the Paul-Ehrlich-Institut: No batch-specific increases of reports of suspected vaccine side effects after COVID-19 vaccinations with Comirnaty
21.07.2023 International Coalition of Medicines Regulatory Agencies (ICMRA) Statements with Participation of the Paul-Ehrlich-Institut
29.06.2023 Statement from the Paul-Ehrlich-Institut on "Post-Vac Syndrome" after COVID-19 Vaccination  
10.06.2022 Statement: Many Rapid Tests Detect Omicron
31.03.2022 Statement: Use of Secondary Data in COVID-19 Vaccine Pharmacovigilance
05.11.2021 Statement: Clinical Trial of Comirnaty from BioNTech
30.04.2021 Statement: Possible Offerings of COVID-19 Vaccine Dilutions
29.12.2020 Corona Vaccination in Individuals Suffering from Allergies
22.12.2020 Observation of the Spread of a Virus Variant of SARS-CoV-2 in the United Kingdom
14.12.2020 Statement: Pyrogen Testing on Rabbits
13.11.2020 Information on the Development Status of COVID-19 Vaccines
10.09.2020 Statement: Clinical Trial of AstraZeneca put on hold
12.08.2020 Statement: Regulatory Approval in Russia of a COVID-19 Vaccine Developed by Gamaleya Institute
07.01.2020 Joint Letter by the EC, EMA and HMA - Provision of Results for Authorised Clinical Trials in EudraCT (June 2019)
27.05.2019 Statement by the Scientific Advisory Board of the Paul-Ehrlich-Institut on the Quality and Safety of Vaccines (German only)
21.11.2019 Position of Paul-Ehrlich-Institut Regarding the Use of Biosimilars